TY  - GEN
AU  - Falchook,Gerald S
AU  - Wheler,Jennifer J
AU  - Naing,Aung
AU  - Jackson,Edward F
AU  - Janku,Filip
AU  - Hong,David
AU  - Ng,Chaan S
AU  - Tannir,Nizar M
AU  - Lawhorn,Kristie N
AU  - Huang,Mei
AU  - Angelo,Laura S
AU  - Vishwamitra,Deeksha
AU  - Hess,Kenneth
AU  - Howard,Adrienne N
AU  - Parkhurst,Kristin L
AU  - Amin,Hesham M
AU  - Kurzrock,Razelle
TI  - Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
SN  - 1949-2553
PY  - 2015///0730
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - Boronic Acids
KW  - Bortezomib
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Carcinoma, Renal Cell
KW  - Fatigue
KW  - etiology
KW  - Female
KW  - Humans
KW  - Hypoxia-Inducible Factor 1, alpha Subunit
KW  - antagonists & inhibitors
KW  - Kidney Neoplasms
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neovascularization, Pathologic
KW  - Proteasome Endopeptidase Complex
KW  - drug effects
KW  - Pyrazines
KW  - Thrombocytopenia
KW  - Treatment Outcome
KW  - Vascular Endothelial Growth Factor A
KW  - immunology
KW  - Vascular Endothelial Growth Factor Receptor-2
KW  - metabolism
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.18632/oncotarget.2163
ER  -